港股异动丨多重利好叠加，恒瑞医药AH股齐涨 H股拉升涨超5%

Core Viewpoint - Heng Rui Medicine's A-shares and H-shares have seen significant increases, with H-shares rising over 5% and A-shares approximately 3% following the release of its performance report for the first three quarters of 2025 [1] Financial Performance - The company reported a revenue of 23.188 billion yuan, representing a year-on-year increase of 14.85% [1] - The net profit attributable to shareholders of the listed company was also highlighted, although specific figures were not provided in the text [1] Product Development and Approvals - Heng Rui Medicine's self-developed drug, HR20031 (brand name: Rui Le Tang), a combination of Dapagliflozin and Metformin extended-release tablets, has received approval from the National Medical Products Administration (NMPA) for market launch, marking it as China's first independently developed product of its kind [1] International Collaboration - The company showcased three research achievements at the 2025 American Society of Anesthesiologists (ASA) annual meeting, indicating its commitment to deepening international collaboration and enhancing China's presence in the global anesthesia field [1]